Skip to main content

Table 1 Patient characteristics

From: Does antithrombotic therapy improve survival with colorectal cancer?

Characteristic

Overall, n = 710

Antithrombotic therapy, n = 246

Control, n = 464

p value

Age (years, mean ± SD)

 

73.8 ± 7.8

68.6 ± 11.6

0.01

Gender (n, %)

Male

183(74.3)

276 (59.4)

 
 

Female

63 (25.7)

188 (40.6)

0.01

BMI (kg/m2, mean ± SD)

 

22.3 ± 3.4

23.6 ± 6.7

0.57

ASA score (n, %)

1

0 (0)

63 (13.5)

 
 

2

0 (0)

366 (78.9)

 
 

3

225 (91.5)

22 (5.0)

 
 

4

21 (8.5)

13 (2.6)

0.01

Comorbidities (n, %)

≤1

18 (7.3)

98 (21.1)

 
 

>1

228 (92.7)

366 (78.9)

0.02

Tumor location (n, %)

Right side

103 (41.5)

209 (45.0)

 
 

Left side

67 (27.6)

102 (22.0)

 
 

Rectum

76 (30.9)

153 (33.0)

0.37

Extended resection (n, %)

Yes

22 (8.9)

63 (13.5)

 
 

No

224 (91.1)

401 (86.5)

0.07

Laproscopic surgery (n, %)

Yes

52 (21.1)

121 (26.0)

 
 

No

194 (78.9)

343 (74.0)

0.14

Chemotherapy (n, %)

Yes

120 (48.7)

268 (57.7)

 
 

No

126 (51.3)

196 (42.3)

0.02

Recurrence (n, %)

Yes

36 (14.6)

98 (21.1)

 
 

No

210 (85.4)

366 (78.9)

0.03

T stage (n, %)

0

9 (3.6)

11 (2.3)

 
 

1

50 (20.3)

82 (17.6)

 
 

2

34 (13.8)

44 (9.5)

 
 

3

100 (40.6)

198 (42.7)

 
 

4

53 (21.7)

128 (27.9)

0.15

N stage (n, %)

0

146 (59.3)

281 (60.5)

 
 

1

60 (24.3)

103 (22.2)

 
 

2

33 (13.4)

63 (13.5)

 
 

3

7 (3.0)

16 (3.8)

0.9

M factor (n, %)

0

220 (89.4)

396 (85.3)

 
 

1

26 (10.6)

67 (14.7)

0.14

The number of lymph node metastasis (n, %)

 

1.59 ± 3.15

1.47 ± 2.81

0.6

Lymph node metastasis (n, %)

Yes

103 (41.8)

179 (38.5)

 
 

No

143 (58.2)

285 (61.5)

0.39

Stage (n, %)

0

9 (3.6)

11 (2.4)

 
 

I

65 (26.4)

114 (24.6)

 
 

II

65 (26.4)

142 (30.6)

 
 

IIIa

54 (21.9)

87 (18.7)

 
 

IIIb

21 (8.5)

37 (8.0)

 
 

IV

32 (13.2)

72 (15.7)

0.59

ly (n, %)

0

67 (27.2)

106 (22.8)

 
 

1

140 (56.9)

252 (54.3)

 
 

2

33 (13.4)

89 (19.2)

 
 

3

6 (2.5)

16 (3.7)

0.15

v (n, %)

0

116 (47.2)

202 (43.5)

 
 

1

62 (25.2)

118 (25.4)

 
 

2

61 (24.8)

121 (26.1)

 
 

3

7 (2.8)

22 (5.0)

0.55

R (n, %)

0

222 (90.2)

399 (86.0)

 
 

1

24 (9.8)

64 (14.0)

0.22

Histrogical type (n, %)

Well

212 (86.2)

398 (84.3)

 
 

Other

34 (13.8)

66 (15.7)

0.88

Poorly differentiated adenocarcinoma (n, %)

Yes

18 (7.3)

43 (9.2)

 
 

No

228 (92.7)

421 (90.8)

0.37

Mucinous adenocarcinoma (n, %)

Yes

19 (7.7)

31 (6.7)

 
 

No

227 (92.3)

433 (93.3)

0.61